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Abstract
Background: Chaoshan region, a littoral area of Guangdong province in southern China, has a high incidence of
esophageal squamous cell carcinoma (ESCC). At present, the prognosis of ESCC is still very poor, therefore, there is
urgent need to seek valuable molecular biomarker for prognostic evaluation to guide clinical treatment. GPX2, a
selenoprotein, was exclusively expressed in gastrointestinal tract and has an anti-oxidative damage and anti-tumour
effect in the progress of tumourigenesis.
Methods: We collected 161 ESCC patients samples, among which 83 patients were followed up. We employed
immunochemistry analysis, western blotting and quantitative real-time PCR for measuring the expression of GPX2
within ESCC samples. We analysed the relationship between the expression of GPX2 and clinicopathological
parameters of 161 patients with ESCC by Chi-square or Fisher’s exact test. The survival analysis of GPX2 expression
within ESCC tissues was evaluated by the Kaplan-Meier method and Cox-regression.
Results: A significant higher expression level of GPX2 was detected in tumour tissues compared to that in
non-tumour tissues (P < 0.001). Moreover, GPX2 expression has statistically significant difference in the tumour
histological grade of ESCC (P < 0.001), while there was no statistically significant difference in age, sex, tumour size,
tumour location, gross morphology and clinical TNM stages (P > 0.05). Meanwhile, the expression of GPX2 protein
was obviously down-regulated within poorly differentiated ESCC. Last, survival analysis revealed that tumour
histological grade and clinical TNM stages, both of the clinical pathological parameters of ESCC, were associated
with the prognosis of patients with ESCC (respectively, P = 0.009, HR (95 % CI) = 1.885 (1.212 ~ 2.932); P = 0.007,
HR (95 % CI) = 2.046 (1.318 ~ 3.177)). More importantly, loss expression of GPX2 protein predicted poor prognosis
in patients with ESCC (P < 0.001, HR (95 % CI) = 5.700 (2.337 ~ 13.907)).
Conclusions: Collectively, these results suggested that the expression of GPX2 was significantly up-regulated within
ESCC tumour tissues. GPX2 might be an important predictor for the prognosis of ESCC and a potential target for
intervention and treatment of ESCC.
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Background
Esophageal carcinoma (EC) is one of the most common
digestive tract malignancies worldwide, and respectively
ranks 8th and 6th in terms of cancer incidence and mor-
tality rate [1]. The Chaoshan area of Guangdong prov-
ince in China is a high incidence district of EC, where
the main histologic type of EC is esophageal squamous
cell carcinoma (ESCC). For most patients with EC, the
first time going to a doctor is usually started after dys-
phagia, which means most patients are diagnosed with
EC in the mid-late stage of the disease. Unfortunately,
the 5-year survival rate of patients with EC ranges from
6 to 50 %, but generally less than 30 % [2]. Thus, the
early detection of tumour prognostic factors is essential
to patients with EC.
Glutathione peroxidase 2 (GPX2), also known as the
glutathione peroxidase (GI-GPX), belongs to the anti-
oxidant enzyme glutathione peroxidase family. The
antioxidant enzyme family has eight known glutathione
peroxidases (GPX1-8) in human [3]. Interestingly, the
antioxidant enzyme family obviously exhibits a tissue-
specific expression [4]. GPX2 is exclusively expressed in
gastrointestinal tract, but in human, GPX2 is also
expressed in liver [5], and has been suggested to protect
against oxidative damage from food [6]. At present, the
overexpression of GPX2 protein is detected in neoplas-
tic transformation of squamous epithelia cells [7],
Barrett’s esophagus [8], lung cancer [9], breast cancer
[10], colorectal cancer [11, 12], hepatocellular carcin-
oma [13] and castration-resistant prostate cancer [14].
Intriguingly, GPX2 may be a candidate as a prognostic
marker for castration-resistant prostate cancer [14].
However, the expression of GPX2 within ESCC is rarely
reported, and the relationship between GPX2 expres-
sion and ESCC prognosis is still unclear. In this study,
we found that the expression of GPX2 protein was
significantly up-regulated within ESCC tumour tissues
compared with non-tumour tissues. More importantly,
the expression of GPX2 protein might be correlated
with the prognosis of patients with ESCC.
Methods
Patients and tissue specimen
In this study, all tissue samples were collected from the
Pathology Department of Shantou University Medical
College, and their clinical pathological features and
diagnosis were verified by two pathologists. Patients
who were diagnosed with ESCC and with no radio- or
chemo- preoperative therapy were enrolled in this
study. We collected samples from 78 patients with
ESCC in the year 2012 and separately sampled three
sorts of these samples: tumour tissue (inside tumour),
tumour-proximal non-malignant tissue (PN, within
2 cm from tumour) and distant non-malignant tissue
(DN, over 5 cm away from tumour) (Fig. 1). According
to the above standards, there were 60 patients with
ESCC who has triple samples, namely tumour tissue,
PN tissue and DN tissue. These tissue samples were in
duplicate stored in −80°C freezer and embedded by par-
affin. We also collected paraffin embedded samples
from 83 patients with ESCC in the second half year of
2002 and followed up these patients or their families
from July, 2002 to May, 2008. These samples with
follow-up were only tumour tissues without PN and
DN. On the basis of the 2010 WHO classification of
tumours of digestive system [15], ESCC was divided
into high differentiated ESCC (ESCCI), moderately dif-
ferentiated ESCC (ESCCII) and poorly differentiated
ESCC (ESCCIII). According to the 7th editions of the
Union for International Cancer Control-American Joint
Committee on cancer (UICC-AJCC) TNM staging sys-
tem [16], patients with ESCC was grouped into stages I,
II, III and IV. This study was approved by the ethical
board of Shantou University Medical College.
Immunohistochemical analysis
Immunohistochemical staining was performed using
the Envision Labelled Peroxidase System (Dako, carpin-
teria, CA). For immunohistochemical analysis, deparaf-
finised sections of the tissues were incubated with
1:100 diluted Pierce anti-GPX2 (Rabbit polyclonal anti-
body, PA5-27150, Thermo Fisher Scientific, Taiwan).
The sections were allowed to develop in 3,3-diamino-
benzidine (DAB). Negative [PBS instead of primary
antibody or isotype-matched non-specific IgG (normal
rabbit IgG, A7016, Beyotime, China) (Additional file 1:
Figure S1)] and positive (gastric carcinoma) controls
were used to confirm the specificity of the primary anti-
bodies. After mounting, sections were scanned by
Aperio ePathology AT2 (Leica Biosystems, Germany)
and images were captured using a Aperio ImageScope
Fig. 1 Schematic illustration of tissue sample collection. Samples
without follow-up in this study were collected accordingly: tumour
tissue (inside tumour), tumour-proximal non-malignant tissue (PN,
within 2 cm from tumour) and distant non-malignant tissue (DN,
over 5 cm away from tumour)
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(Version 12.1, Leica Biosystems, Germany) at 40× and
200× magnification. The quantitation of GPX2 cyto-
plasmic immunoreactivity was determinated by the
product of the dyeing intensity and the expression rate.
The dyeing intensity was divided into four degrees
including 0, 1, 2 and 3. When the product was more
than 0.5, the expression of GPX2 protein within ESCC
tissues was defined as GPX2-positive expression (GPX2+);
when less than 0.5, it was defined as GPX2-negative
expression (GPX2-).
RNA preparation and quantitative RT-PCR
The freshly tumour, PN and DN tissue samples from 7
patients with ESCC were stored in −80°C freezer. After
thawing, total RNA was extracted from the freshly tissue
samples using an RNeasy MiNi Kit (TianGen, Beijing,
China). Reverse transcription was performed using a
PrimeScript RT Master Mix Perfect Real Time 100 Reac-
tions Kit (TaKaRa, Dalian, China). For measurement of
GPX2 mRNA level, RT-PCR was performed with SYBR
Premix EX TaqTM II (TaKaRa, Dalian, China). Primer
Fig. 2 GPX2 overexpression in tumour tissues compared with non-tumour tissues including PN and DN tissues. a Representative IHC images of
GPX2 staining in tumour, PN and DN tissues. b The immunochemistry analysis of the relative expression of GPX2 in tumour, PN and DN tissues according
to staining intensity. There is a statistically significant difference in GPX2 protein expression of tumour tissues compared with compared with non-tumour
tissues including PN and DN tissues (P< 0.001) studied by the independent-samples test. c The relative level of GPX2 mRNA expression in tumour, PN and
DN tissues. There is statistically significant difference in GPX2 mRNA expression of tumour tissues compared with compared with non-tumour tissues
including PN and DN tissues (P= 0.027) studied by the independent-samples test. d Western blot analysis of GPX2 protein in tumour, PN and DN tissues
from two patients within ESCC. Obviously, GPX2 protein was overexpressed in tumor tissues compared with PN and DN tissues. e Western blot analysis of
GPX2 protein in ESCCI, ESCCII and ESCCIII tissues from six patients with ESCC. Obviously, the expression of GPX2 protein was down-regulated in ESCCIII
tissues compared with ESCCI and ESCCII tissues. M: protein marker; TM: tumour;I: ESCCI; II: ESCCII; III: ESCCIII
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sequences were 5’ - TGCAACCAATTTGGACATCAG - 3’
and 5’- AGACAGGATGCTCGTTCTGC-3’ for human
GPX2; 5’-CAGCCTCAAGATCATCAGCA - 3’ and 5’ -
ATGATGTTCTGGAGAGCCCC - 3’ for human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The
following experiments were performed in triplicate in a
7300 Real-Time PCR System (ABI, USA). Analysis of rela-
tive GPX2 gene expression data was using real-time quanti-
tative PCR and the the 2−ΔΔCT Method [17].
Western blotting analysis
The freshly tumour, PN and DN tissue samples from 6
patients with ESCC and freshly tumour tissue samples
from other 6 patients with ESCC were lysed in RIPA
buffer in the presence of 1 × protease inhibitor cocktail
(Sigma-Aldrich, USA). 50 μg of total protein was re-
solved on 10 % sodium dodecyl sulfate-polyacrylamide
gels and transferred onto PVDF membranes (0.45 μm,
Amersham Pharmacia, USA). The expression level of
GPX2 was assessed by Pierce anti-GPX2 (Rabbit poly-
clonal antibody, 24 kDa, 1:1000, PA5-27150, Thermo
Fisher Scientific, Taiwan). Beta actin (β-actin) expression
was evaluated to confirm equal amounts of protein load-
ing using a mouse monoclonal anti-beta-actin antibody
(42 kDa, 1:10000, Mab1445, Sigma-Aldrich, USA). After
incubated with Goat anti-rabbit or mouse antibody
(1:10000, 680RD, LI-COR biosciences, Germany), identi-
fication of the bands was scanned by Odyssey infrared
imaging system (LI-COR biosciences, Germany). The
outcome images were exported by Odyssey application
software (Version 3.0, LI-COR biosciences, Germany).
Statistical analysis
All data was analysed with SPSS statistics software (Ver-
sion 19.0, Chicago, IL, USA). Relationships between
GPX2 expression and ESCC clinicopathological features
were studied using the Chi-square test or Fisher’s exact
test. The GPX2 expression of tumor tissues compared
with that of non-tumour tissues including PN and DN
tissues was studied by the independent-samples test.
Survival time was calculated from the date of surgery to
the date of death or the last follow-up time. The correl-
ation of different survival time with ESSC characteristics,
clinical features and GPX2 were evaluated by using the
Kaplan-Meier method. The log-rank test was used to
analyse survival differences. The hazard ratio (HR) and
95 % confidence interval (CI) were calculated by univari-
ate or multivariate Cox regression analysis. In order to
identify the predictors of ESCC outcome, we used Cox
stepwise regression for calculation with a significance
level of P < 0.05 for entering and P > 0.10 for removing
the respective explanatory variables. A P value of less
than 0.05 was considered as statistically significant
difference.
Results
GPX2 protein was overexpressed within ESCC tumour tissues
As detected in other tumours, the expression of GPX2
protein was markedly up-regulated within ESCC tumour
tissues. In this study, immunohistochemistry (IHC) results
of triple samples of 60 patients with ESCC showed that the
significant higher expression level of GPX2 protein was
detected in ESCC tumour tissues compared with non-
tumour including PN and DN tissues (P < 0.001) (Fig. 2a
and b). To further verify the IHC results of the expression
of GPX2 protein, western blotting and RT-PCR were
employed by this study. Under equal-weight protein
samples, western blotting results showed that GPX2 was
obviously overexpressed within ESCC tumour tissues
compared with non-tumour including PN and DN (Fig. 2d
and Additional file 2: Figure S2). The interesting
Table 1 The relationship between GPX2 protein expression and
ESCC patients’ clinicopathological characteristics
Clinical features Cases GPX2+ GPX2− P value
Age
≤ 58 years 83 70 13 0.539
> 58 years 78 62 16
Sex
Male 117 95 22 0.670
Female 44 37 7
Size
≤ 4.5 cm 98 83 15 0.265
> 4.5 cm 63 49 14
Site
Upper 13 12 1 0.380
Middle 107 89 18
Below 41 31 10
Gross morphology
Medullary 79 69 10 0.258
Umbrella 11 9 2
Ulcer 54 40 14
Stenosis 17 14 3
Histological grade
I 46 41 5 <0.001
II 94 86 8
III 21 5 16
TNM stages
I~II 86 75 11 0.118
III 73 55 18
IV 2 2 0
GPX2+: ESCC with GPX2-positive expression; GPX2−: ESCC with
GPX2-negative expression
Histological grade: I, high differentiated ESCC; II, moderately differentiated
ESCC; III, poorly differentiated ESCC
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phenomenon was also simultaneously demonstrated by the
RT-PCR result of GPX2 mRNA (P = 0.027) (Fig. 2c). Hence
the expression of GPX2 protein was significantly up-
regulated within ESCC tumour tissues.
Expression of GPX2 protein significantly correlated with
tumour histological grade of ESCC
According to the IHC results of GPX2 protein expression
within ESCC tumour tissues, we divided ESCC patients into
two groups, namely GPX2-positive expression (GPX2+)
group and GPX2-negative expression (GPX2-) group. We
found that GPX2 protein was expressed positively in 82.0 %
(132 out of 161) of the cases of ESCC. Further, we analysed
the relationship between the expression of GPX2 protein
and ESCC patients’ clinicopathological characteristics. We
found that the expression of GPX2 protein has statistically
significant difference in the tumour histological grade of
ESCC (P < 0.001), while there were no statistically signifi-
cant difference in age, sex, tumour size, tumour location,
gross morphology and clinical TNM stages (P > 0.05)
(Table 1). Therefore, the expression of GPX2 protein was
significantly related to the tumour histological grade of
ESCC. Furthermore, we detected another important
phenomenon that GPX2 protein was hardly expressed
within ESCCIII compared with ESCCIand ESCCII (Fig. 2e).
Negatively-expression of GPX2 protein predicted a poorer
prognosis in ESCC patients
In the prognostic analysis of 83 ESCC patients with
follow-up, firstly, survival analysis of the clinical
Table 2 Survival analysis of the clinical pathological parameters
Clinical features Cases Mortality MST (95 % CI) Log-rank P value HR (95 % CI)
Age
≤ 58 years 45 35 26 (16.141~38.859) 0.850 1.049 (0.637~1.725)
> 58 years 38 28 18 (5.918~30.082)
Sex
Male 60 46 26 (13.348~38.652) 0.796 1.075 (0.616~1.876)
Female 23 17 18 (8.609~27.391)
Size
≤ 4.5 cm 48 35 29 (17.118~40.882) 0.339 1.270 (0.772~2.088)
> 4.5 cm 35 28 19 (4.512~33.488)
Site
Upper 9 6 33 (0~73.905) 0.028 1.803 (0.992~3.278)
Middle 65 48 29 (18.467~39.533)
Below 9 9 11 (5.156~16.844)
Gross morphology
Medullary 62 46 30 (9.755~50.245) <0.001 1.252 (0.942~1.663)
Umbrella 5 4 9 (6.853~11.147)
Ulcer 13 10 20 (10.605~29.395)
Stenosis 3 3 6 (4.400~7.600)
Histological grade
I 32 20 47 (10.966~83.034) 0.009 1.885 (1.212~2.932)
II 46 38 20 (8.616~31.384)
III 5 5 8 (5.853~10.147)
TNM stages
I~II 49 32 42 (22.796~61.204) 0.007 2.046 (1.318~3.177)
III 32 29 14 (6.608~21.392)
IV 2 2 -
Treatment
No 41 31 19 (3.944~34.056) 0.529 0.855 (0.522~1.402)
Yes 42 32 22 (10.886~33.114)
Histological grade: I, high differentiated ESCC; II, moderately differentiated ESCC; III, poorly differentiated ESCC
Treatment: Radiotherapy or chemotherapy after surgery
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pathological parameters showed that both tumour
histological grade and clinical TNM stages were not-
ably related to the prognosis of patients with ESCC
(respectively, P = 0.009, HR (95 % CI) = 1.885 (1.212 ~
2.932); P = 0.007, HR (95 % CI) = 2.046 (1.318 ~
3.177)), while there were no statistically significant dif-
ferences in age, sex, tumour size, tumour location,
gross morphology and radiotherapy or chemotherapy
after surgery (P > 0.05 or the lower limit of HR (95 %
CI) < 1) (Table 2). Secondly, we carried on the prog-
nostic analysis of the expression of GPX2 protein in
83 ESCC patients with follow-up. Those with
negative-expression GPX2 in their biopsy specimen
had significantly poorer prognosis than those with
positive-expression GPX2 (P < 0.001) (Table 3 and
Fig. 3). One-year survival rates of both positive-
expression group and negative-expression group of
GPX2 protein were 71.1 % and 0, and median survival
time (MST) were 29 (15.117 ~ 42.883) and 8 (5.434 ~
10.566), respectively (Table 3). In the Cox regression
model analysis, we found that the expression of GPX2
protein (P < 0.001, HR (95 % CI) = 5.700 (2.337 ~
13.907)) and tumour histological grade (P = 0.01, HR
(95 % CI) = 1.739 (1.143 ~ 2.646)) influenced on the
long-term survival of ESCC patients, and were death
risk factors of ESCC patients (Table 4). Adjusting for
the other factor, the death risk of GPX2-negative
expression was 4.7 times more than GPX2-positive
expression. Thus negatively-expression of GPX2 pro-
tein predicted significantly a poorer prognosis in
patients with ESCC.
Discussion
EC is an aggressive malignant neoplasm with a poor prog-
nosis. The 5-year survival rates of patients with EC ranges
from 15 to 24% [18]. In China, EC ranks 5th in the most
common cancer and 4th in the leading cause of cancer
death [19]. The two major histological subtypes of EC is
ESCC and esophageal adenocarcinomas (EAC). In
contrast to EAC, ESCC has a high prevalence in Asia and
South Africa [20]. The consumption of hot food and bev-
erages is considered as an increased risk of esophageal
cancer, particularly ESCC [21]. The traditional treatment,
like surgery, radiotherapy and chemotherapy, do not bring
a greater benefits to patients with EC. Even worse, there is
no a better prognostic factor which can predict the life
expectancy of patients with EC. Therefore, the prognostic
factor of EC should deserve to make it.
Glutathione peroxidases (GPXs) is a family of antioxi-
dant enzymes. The biochemical function of GPXs is to
reduce H2O2 or organic hydroperoxides to water or their
corresponding alcohols respectively [22]. At the present,
the GPX family consists of eight members: GPX1,
GPX2, GPX3, GPX4, GPX5, GPX6, GPX7 and GPX8 [4].
In particular, GPX2, also a selenium-dependent enzyme,
is specifically expressed within the gastrointestinal tract
in human being [5]. Therefore, GPX2 can be considered
as one of the most important defence systems against
oxidative damage from the consumption of hot food and
beverages. Impressively, GPX2 has an anti-inflammatory
and anti-tumour effect in the course of the tumorigen-
esis [23]. Compared with normal tissues, cancer cells
produce a higher level of reactive oxygen species (ROS)
[24] and cancer tissues suffer from a severer oxidative
damage [25, 26]. As expected, the expression of GPX2
protein is up-regulated within various cancer tissues.
Based on epidemiological study, the reproducibility of a
semi-quantitative food frequency questionnaire showed
the daily intake of selenium was 81.8~231.2 μg in the diets
Table 3 Survival analysis of 83 patients between GPX2 + and
GPX2 −





+ 76 56 29 (15.117~42.883) 71.1 22.587 <0.001
− 7 7 8 (5.434~10.566) 0
GPX2+: ESCC with GPX2-positive expression; GPX2−: ESCC with
GPX2-negative expression
Fig. 3 Prognostic analysis of 83 patients with ESCC according to
presence of and absence of GPX2 expression. GPX2 positive patients:
n = 76, GPX2 negative patients: n = 7, P < 0.001
Table 4 Cox regression of 83 patients with ESCC
Variable B SE (B) Wald χ2 P value HR HR 95 % CI
GPX2 1.741 0.455 14.630 <0.001 5.700 2.337~13.907
Histological grade 0.553 0.214 6.688 0.010 1.739 1.143~2.646
Lei et al. BMC Cancer  (2016) 16:410 Page 6 of 8
of Chaoshan inhabitants [27], and in our previous study,
the hair selenium level of Chaoshan inhabitants was about
0.48 mg/L [28]. According to the 50~250 μg of suitable
range of the daily selenium intake of Chinese residents
[29], the selenium supply of inhabitants in Chaoshan
region is appropriate. Convincingly, GPX2 protein was
significantly overexpressed within ESCC tumour tissues
compared with non-tumour tissues in this study. GPX2
may play an important role in anti-tumour within ESCC
tumour tissues, while ESCC with a loss expression of
GPX2 protein is prone to progress to the poor differenti-
ated ESCC. Because of the limited samples with follow-up,
whether or not GPX2 is expected to be a monitoring
prognostic factor of patients with ESCC, it is still open for
further experimentation.
Conclusions
To sum up, the expression of GPX2 protein was signifi-
cantly up-regulated within ESCC tumour tissues compared
with non-tumour tissues. GPX2 might be an important
predictor for the prognosis of patients with ESCC.
Additional files
Additional file 1: Figure S1. Representative IHC images of normal
rabbit IgG as negative control. Images were captured using a Leica IM50
microscope (Imagic Bildverarbeitung AG, Wetzlar, Germany) at 40× (A)
and 200× (B) magnification. (TIF 4013 kb)
Additional file 2: Figure S2. Western blot analysis of GPX2 protein in
tumour, PN and DN tissues from other 4 patients with ESCC. Obviously,
GPX2 protein was overexpressed in tumor tissues compared with PN and
DN tissues. M: protein marker; TM: tumour;I: ESCCI; II: ESCCII; III: ESCCIII.
(TIF 1324 kb)
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